Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.75B P/E - EPS this Y 15.10% Ern Qtrly Grth -
Income -298.33M Forward P/E -10.13 EPS next Y 40.40% 50D Avg Chg -7.00%
Sales 322.71M PEG 0.11 EPS past 5Y - 200D Avg Chg -19.00%
Dividend N/A Price/Book 2.62 EPS next 5Y -77.40% 52W High Chg -49.00%
Recommedations 1.70 Quick Ratio 2.81 Shares Outstanding 99.61M 52W Low Chg 30.00%
Insider Own 2.18% ROA -21.13% Shares Float 891.33M Beta 1.06
Inst Own 44.76% ROE -36.46% Shares Shorted/Prior 5.42M/4.71M Price 27.26
Gross Margin -16.68% Profit Margin -92.45% Avg. Volume 597,895 Target Price 49.54
Oper. Margin -75.68% Earnings Date Nov 5 Volume 669,182 Change -7.09%
About Zai Lab Limited

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Zai Lab Limited News
12/24/24 Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock?
12/23/24 Zai Lab (NASDAQ:ZLAB) shareholders have endured a 59% loss from investing in the stock three years ago
12/12/24 Zai Lab Announces Participation in Investor Conference in January 2025
12/03/24 Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint
12/02/24 NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
12/02/24 Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
11/27/24 Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
11/26/24 Exploring Three High Growth Tech Stocks in the United States
11/22/24 Zai Lab and Pfizer to commercialise XACDURO in China
11/21/24 Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
11/18/24 Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
11/15/24 Analyst Estimates: Here's What Brokers Think Of Zai Lab Limited (NASDAQ:ZLAB) After Its Third-Quarter Report
11/14/24 Zai Lab Announces Pricing of Public Offering of American Depositary Shares
11/14/24 Zai Lab Third Quarter 2024 Earnings: EPS Beats Expectations
11/13/24 Zai Lab Announces Proposed Public Offering of American Depositary Shares
11/13/24 Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Path to Profitability
11/12/24 Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics
11/12/24 Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo
11/12/24 Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
11/11/24 Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Amado Rafael See Remarks See Remarks Dec 29 Sell 26.3 19,363 509,247 22,637 01/03/24
Du Ying Chairperson & CEO Chairperson & CEO Jan 01 Sell 26.12 8,380 218,886 1,133,450 01/03/24
Reinhart Harald See Remarks See Remarks Jan 01 Sell 26.12 4,803 125,454 46,060 01/03/24
Edmondson Frazor Titus III Chief Legal Officer Chief Legal Officer Jan 01 Sell 26.12 4,803 125,454 30,005 01/03/24
Smiley Joshua L See Remarks See Remarks Dec 14 Buy 29.9 4,000 119,600 20,527 12/18/23
Smiley Joshua L See Remarks See Remarks Nov 16 Buy 26.93 5,000 134,650 16,527 11/16/23
WIRTH PETER Director Director Dec 08 Sell 35.35 7,852 277,568 12/09/22
Reinhart Harald See Remarks See Remarks Apr 01 Option 3 1,854 5,562 26,715 11/17/22
Reinhart Harald See Remarks See Remarks Apr 01 Sell 40.02 1,854 74,197 24,861 11/17/22
Edmondson Frazor Titus III Chief Legal Officer Chief Legal Officer Aug 17 Option 43.52 4,850 211,072 9,146 08/19/22
DIEKMAN JOHN D Director Director Feb 04 Sell 50.17 1,000 50,170 67,615 02/07/22
Lis William Director Director Jan 20 Sell 53.40 1,926 102,848 34,114 01/21/22
Fu Tao President & COO President & COO Oct 28 Sell 104.81 10,000 1,048,100 77,500 10/29/21
Fu Tao President & COO President & COO Oct 14 Sell 102.79 10,000 1,027,900 87,500 10/14/21
Fu Tao President & COO President & COO Sep 16 Sell 129.22 9,900 1,279,278 207,600 09/16/21
Fu Tao President & COO President & COO Sep 16 Option 18.92 10,000 189,200 217,500 09/16/21
Reinhart Harald Chief Medical Office.. Chief Medical Officer Sep 08 Sell 148.75 10,000 1,487,500 09/08/21
Reinhart Harald Chief Medical Office.. Chief Medical Officer Sep 08 Option 3 10,000 30,000 10,000 09/08/21
Du Ying Chairwoman & CEO Chairwoman & CEO Sep 08 Sell 149.07 29,785 4,440,050 1,008,653 09/08/21
Du Ying Chairwoman & CEO Chairwoman & CEO Sep 03 Sell 146.2 81,326 11,889,861 1,038,438 09/03/21
Du Ying Chairwoman & CEO Chairwoman & CEO Sep 03 Option 0.6 111,111 66,667 1,119,764 09/03/21
Reinhart Harald Chief Medical Office.. Chief Medical Officer Aug 25 Sell 139.18 16,000 2,226,880 08/25/21
Reinhart Harald Chief Medical Office.. Chief Medical Officer Aug 25 Option 17.99 16,000 287,840 8,000 08/25/21
Du Ying Chairwoman & CEO Chairwoman & CEO Aug 03 Option 0.6 111,111 66,667 1,116,649 08/03/21